keyword
MENU ▼
Read by QxMD icon Read
search

dopaminergic treatment

keyword
https://www.readbyqxmd.com/read/29164312/efficacy-and-safety-of-rotigotine-in-elderly-patients-with-parkinson-s-disease-in-comparison-with-the-non-elderly-a-post-hoc-analysis-of-randomized-double-blind-placebo-controlled-trials
#1
Masahiro Nomoto, Hirotaka Iwaki, Hiroyuki Kondo, Masaya Sakurai
Rotigotine-a non-ergot dopamine agonist-has two advantages; it can stimulate all dopamine receptors (D1-D5) like innate dopamine, and its transdermal administration provides continuous dopaminergic stimulation. The age of the patient impacts the effect and adverse events of anti-parkinsonian treatment. We conducted a post hoc analysis on three randomized, double-blind, placebo-controlled trials performed in Japan to clarify the difference of anti-parkinsonian treatment in elderly and non-elderly patients. Data from two combination therapy trials (with levodopa) in advanced stage Parkinson's disease patients and one monotherapy trial in early stage patients were pooled and grouped by age (non-elderly aged < 70, elderly aged 70 +)...
November 21, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/29163234/a-comparison-of-treatment-seeking-behavioral-addiction-patients-with-and-without-parkinson-s-disease
#2
Anne Sauvaget, Susana Jiménez-Murcia, Fernando Fernández-Aranda, Roser Granero, Marie Grall-Bronnec, Caroline Victorri-Vigneau, Samuel Bulteau, Pascal Derkinderen, Jean M Vanelle, Anders Hakansson, Gemma Mestre-Bach, Trevor Steward, José M Menchón
The administration of dopaminergic medication to treat the symptoms of Parkinson's disease (PD) is associated with addictive behaviors and impulse control disorders. Little is known, however, on how PD patients differ from other patients seeking treatments for behavioral addictions. The aim of this study was to compare the characteristics of behavioral addiction patients with and without PD. N = 2,460 treatment-seeking men diagnosed with a behavioral addiction were recruited from a university hospital. Sociodemographic, impulsivity [Barratt Impulsiveness Scale (BIS-11)], and personality [Temperament and Character Inventory-Revised (TCI-R)] measures were taken upon admission to outpatient treatment...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29160692/s100a9-protein-aggregates-boost-hippocampal-glutamate-modifying-monoaminergic-neurochemistry-a-glutamate-antibody-sensitive-outcome-on-alzheimer-like-memory-decline
#3
Marina A Gruden, Tatiana V Davydova, Vladimir S Kudrin, Chao Wang, Victor B Narkevich, Ludmilla A Morozova-Roche, Robert D E Sewell
Alzheimer's disease (AD) involves dementia conceivably arising from integrated inflammatory processes, amyloidogenesis and neuronal apoptosis. Glutamate can also cause neuronal death via excitotoxicity and this is similarly implicated in some neurological diseases. The aim was to examine treatment with in vitro generated pro-inflammatory protein S100A9 aggregate species alone or with glutamate antibodies (Glu-Abs) on Morris water maze (MWM) spatial learning and memory performance in 12-month old mice. Amino acid and monoamine cerebral neurotransmitter metabolic changes were concurrently monitored...
November 21, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29158943/depression-in-parkinson-s-disease-the-contribution-from-animal-studies
#4
REVIEW
Jéssica Lopes Fontoura, Camila Baptista, Flávia de Brito Pedroso, José Augusto Pochapski, Edmar Miyoshi, Marcelo Machado Ferro
Besides being better known for causing motor impairments, Parkinson's disease (PD) can also cause many nonmotor symptoms, like depression and anxiety, which can cause significant loss of life quality and may not respond to regular drugs treatment. In this review, we discuss the depression in PD, based on data from studies in humans and rodents. Depression frequency seems higher in PD patients than in general population, despite high variation in data due to diagnosis disparities. Development of depression in PD seems more likely to be caused by the nigrostriatal pathway degeneration than as a consequence of the awareness of disease prognostic, and it seems to be related to dopaminergic, noradrenergic, and serotoninergic synapses deficits...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/29158578/ketamine-and-its-metabolite-2r-6r-hydroxynorketamine-induce-lasting-alterations-in-glutamatergic-synaptic-plasticity-in-the-mesolimbic-circuit
#5
N Yao, O Skiteva, X Zhang, P Svenningsson, K Chergui
Low doses of ketamine trigger rapid and lasting antidepressant effects after one injection in treatment-resistant patients with major depressive disorder. Modulation of AMPA receptors (AMPARs) in the hippocampus and prefrontal cortex is suggested to mediate the antidepressant action of ketamine and of one of its metabolites (2R,6R)-hydroxynorketamine ((2R,6R)-HNK). We have examined whether ketamine and (2R,6R)-HNK affect glutamatergic transmission and plasticity in the mesolimbic system, brain regions known to have key roles in reward-motivated behaviors, mood and hedonic drive...
November 21, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/29158176/decreased-mcl-1-protein-level-in-the-striatum-of-1-methyl-4-phenyl-1-2-3-6-tetrahydropyridine-mptp-treated-mice
#6
Edward Lu, Sumit Sarkar, James Raymick, Merle G Paule, Qiang Gu
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a well-known neurotoxicant that can selectively destroy dopaminergic neurons and MPTP-treated animals are often used as models for studying aspects of Parkinson's disease (PD). While apoptosis has been suggested as a possible mechanism underlying MPTP-induced cell death and several apoptosis-associated proteins have been implicated in MPTP-animal models, relevant information regarding the possible involvement of Mcl-1 (myeloid cell leukemia 1) protein is missing...
November 17, 2017: Brain Research
https://www.readbyqxmd.com/read/29157667/a-case-of-multiple-system-atrophy-parkinsonian-type-with-stuttering-and-palilalia-like-dysfluencies-and-putaminal-atrophy
#7
Yoshikazu Kikuchi, Toshiro Umezaki, Taira Uehara, Hiroo Yamaguchi, Koji Yamashita, Akio Hiwatashi, Motohiro Sawatsubashi, Kazuo Adachi, Yumi Yamaguchi, Daisuke Murakami, Jun-Ichi Kira, Takashi Nakagawa
Both developmental and acquired stuttering are related to the function of the basal ganglia-thalamocortical loop, which includes the putamen. Here, we present a case of stuttering- and palilalia-like dysfluencies that manifested as an early symptom of multiple system atrophy-parkinsonian type (MSA-P) and bilateral atrophy of the putamen. The patient was a 72-year-old man with no history of developmental stuttering who presented with a stutter for consultation with our otorhinolaryngology department. The patient was diagnosed with MSA-P based on parkinsonism, autonomic dysfunction, and bilateral putaminal atrophy revealed by T2-weighted magnetic resonance imaging...
November 14, 2017: Journal of Fluency Disorders
https://www.readbyqxmd.com/read/29157488/l%C3%A2-hypophyse-et-ses-traitements-comment-peuvent-ils-influer-sur-le-comportement-the-pituitary-and-its-treatments-how-can-they-influence-behaviour
#8
C Mouly, F Borson-Chazot, P Caron
Behaviour may be influenced by pituitary hormones or treatments. Dopamine agonist (DA) indicated in prolactinomas treatment can cause side effects, and especially impulse control disorders. In the context of prolactinomas treatment, impulse control disorders (ICD) have been reported like gambling, compulsive shopping, but mostly hypersexuality. These ICD can occur with low AD doses, and seem to be independent of type of molecule and psychiatric medical history. The main pathophysiologic hypothesis is a dysregulation of dopaminergic pathway involved in reward system...
October 2017: Annales D'endocrinologie
https://www.readbyqxmd.com/read/29155259/polyi-c-model-of-schizophrenia-in-rats-induces-functional-brain-changes-detected-by-mri-irreversible-by-aripiprazole-treatment
#9
Eva Drazanova, Jana Ruda-Kucerova, Lucie Kratka, Katerina Horska, Regina Demlova, Zenon Starcuk, Tomas Kasparek
BACKGROUND AND PURPOSE: One of the hallmarks of schizophrenia is altered brain structure, potentially due to antipsychotic treatment, the disorder itself or both. It was proposed that functional changes may precede the structural ones. In order to understand and potentially prevent this unwanted process, brain function assessment should be validated as a diagnostic tool. METHODS: We used Arterial Spin Labelling MRI technique for the evaluation of brain perfusion in several brain regions in a neurodevelopmental poly(I:C) model of schizophrenia (8 mg/kg on a gestational day 15) in rats taking into account sex-dependent effects and chronic treatment with aripiprazole (30 days), an atypical antipsychotic acting as a partial agonist on dopaminergic receptors...
November 16, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/29151060/genetics-of-parkinson-s-disease-and-related-disorders
#10
REVIEW
Pei-Lan Zhang, Yan Chen, Chen-Hao Zhang, Yu-Xin Wang, Pedro Fernandez-Funez
Parkinson's disease (PD) is a complex and heterogeneous neurological condition characterised mainly by bradykinesia, resting tremor, rigidity and postural instability, symptoms that together comprise the parkinsonian syndrome. Non-motor symptoms preceding and following clinical onset are also helpful diagnostic markers revealing a widespread and progressive pathology. Many other neurological conditions also include parkinsonism as primary or secondary symptom, confounding their diagnosis and treatment. Although overall disease course and end-stage pathological examination single out these conditions, the significant overlaps suggest that they are part of a continuous disease spectrum...
November 18, 2017: Journal of Medical Genetics
https://www.readbyqxmd.com/read/29150520/dopaminergic-neurotoxins-induce-cell-death-by-attenuating-nf-%C3%AE%C2%BAb-mediated-regulation-of-trpc1-expression-and-autophagy
#11
Pramod Sukumaran, Yuyang Sun, Neil Antonson, Brij B Singh
Alterations in Ca(2+) homeostasis affect neuronal survival. However, the identity of Ca(2+) channels and the mechanisms underlying neurotoxin-induced neuronal degeneration are not well understood. In this study, the dopaminergic neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl -4-phenylpyridium ions (MPP(+)/MPTP), which mimic Parkinson's disease (PD), induced neuronal degeneration by decreasing store-mediated Ca(2+) entry. The function of the transient receptor potential canonical (TRPC)-1 channel was decreased upon exposure to the neurotoxins, followed by a decrease in TRPC1 expression...
November 17, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29149825/dopamine-agonists-and-neurodegenerative-disorders
#12
Saba Khanam, Yasir Hasan Siddique
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite of many researches, there is still no cure for this disease. Levodopa is first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but also have side effects. Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects...
November 17, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/29147910/therapeutic-activities-of-dj-1-and-its-binding-compounds-against-neurodegenerative-diseases
#13
Masatoshi Inden, Daijiro Yanagisawa, Masanori Hijioka, Hiroyoshi Ariga, Yoshihisa Kitamura
Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway. Loss-of-function mutations in the gene encoding PARK7/DJ-1 were identified in familial PD. Wild-type DJ-1 acts as an oxidative stress sensor in neural cells. Previously, we identified binding compounds of DJ-1, including UCP0045037/compound A, UCP0054278/compound B, and compound-23 (comp-23), by in silico virtual screening. These compounds prevented oxidative stress-induced dopaminergic neuronal death and restored locomotion defects in animal models of PD...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29145874/peripheral-immune-tolerance-alleviates-the-intracranial-lipopolysaccharide-injection-induced-neuroinflammation-and-protects-the-dopaminergic-neurons-from-neuroinflammation-related-neurotoxicity
#14
Yang Liu, Xin Xie, Li-Ping Xia, Hong Lv, Fan Lou, Yan Ren, Zhi-Yi He, Xiao-Guang Luo
BACKGROUND: Neuroinflammation plays a critical role in the onset and development of neurodegeneration disorders such as Parkinson's disease. The immune activities of the central nervous system are profoundly affected by peripheral immune activities. Immune tolerance refers to the unresponsiveness of the immune system to continuous or repeated stimulation to avoid excessive inflammation and unnecessary by-stander injury in the face of continuous antigen threat. It has been proved that the immune tolerance could suppress the development of various peripheral inflammation-related diseases...
November 16, 2017: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29143216/self-perception-and-determinants-of-color-vision-in-parkinson-s-disease
#15
Alexander U Brandt, Hanna G Zimmermann, Timm Oberwahrenbrock, Justine Isensee, Thomas Müller, Friedemann Paul
Visual dysfunction is common in patients with Parkinson's disease (PD). The objective of this study was to investigate the perceived impact of visual dysfunction and especially color vision loss on PD patients, and to identify retinal and disease factors associated with color vision. Thirty PD patients and thirty-four healthy controls were included. Participants performed the Farnsworth-Munsell Hue-100 test (FMT). Patients answered the National Eye Institute Visual Function Questionnaire (NEI-VFQ), Unified Parkinson's Disease Rating Scale (UPDRS) assessment, and underwent optical coherence tomography with measurement of retinal nerve fiber layer, ganglion cell layer + inner plexiform layer (GCIPL), and outer nuclear and photoreceptor layer...
November 15, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29138117/melatonin-protects-against-behavioral-deficits-dopamine-loss-and-oxidative-stress-in-homocysteine-model-of-parkinson-s-disease
#16
Rajib Paul, Banashree Chetia Phukan, Arokiasamy Justin Thenmozhi, Thamilarasan Manivasagam, Pallab Bhattacharya, Anupom Borah
AIM: Hyperhomocysteinemia and homocysteine (Hcy) mediated dopaminergic neurotoxicity is a matter of concern in the pathophysiology of Parkinson's disease (PD). Our previous study established the involvement of oxidative stress in the substantia nigra (SN) of Hcy rat model of PD; however, the role of antioxidants, such as melatonin, was not tested in this model. MAIN METHODS: Melatonin (10, 20 and 30mg/kg, i.p.) was administered to rats injected with Hcy in right SN (1...
November 11, 2017: Life Sciences
https://www.readbyqxmd.com/read/29137045/the-significance-of-uric-acid-in-the-diagnosis-and-treatment-of-parkinson-disease-an-updated-systemic-review
#17
Zhange Yu, Shuai Zhang, Dongdong Wang, Meng Fan, Fuqiang Gao, Wei Sun, Zirong Li, Shiliang Li
BACKGROUND: Parkinson disease (PD) is a neurodegenerative disease characterized by chronic and progressive loss of dopaminergic neurons in substansia nigra pars compacta. Oxidative stress is proposed to play a critical role in the pathogenesis of PD. Uric acid (UA), as an important physiological antioxidant, is identified a molecular predictor associated with a decreased risk and a slower disease progression for PD and potential neuroprotectant of PD by increasing epidemiological and clinical evidences...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29132545/nanoformulation-a-useful-therapeutic-strategy-for-improving-neuroprotection-and-the-neurorestorative-potential-in-experimental-models-of-parkinson-s-disease
#18
Jose V Lafuente, Catalina Requejo, Alejandro Carrasco, Harkaitz Bengoetxea
Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, but current therapies are only symptomatic. Experimental models are necessary to go deeper in the comprehension of pathophysiological mechanism and to assess new therapeutic strategies. The unilateral 6-hydroxydopamine (6-OHDA) lesion either in medial forebrain bundle (MFB) or into the striatum in rats affords to study various stages of PD depending on the evolution time lapsed. A promising alternative to address the neurodegenerative process is the use of neurotrophic factors; but its clinical use has been limited due to its short half-life and rapid degradation after in vivo administration, along with difficulties for crossing the blood-brain barrier (BBB)...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/29130486/rtp801-is-a-critical-factor-in-the-neurodegeneration-process-of-a53t-alpha-synuclein-in-a-mouse-model-of-parkinson-s-disease-under-chronic-restraint-stress
#19
Zhao Zhang, Shi-Feng Chu, Sha-Sha Wang, Yi-Na Jiang, Yan Gao, Peng-Fei Yang, Qi-Di Ai, Nai-Hong Chen
BACKGROUND AND PURPOSE: The incidence of Parkinson's disease exhibited a younger tendency in recent years with the constantly increased stressors of modern society, but this relationship remains obscured. We performed this study to investigate whether stress contributes to this tendency and identify the executor during this process. EXPERIMENTAL APPROACH: Ten-month-old α-synuclein A53T mice, a PD mice model, were treated with chronic restraint stress (CRS) to simulate a PD-sensitive person with constant stress stimulation...
November 11, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29130466/-safinamide-from-daily-clinical-practice-first-clinical-steps
#20
J Pagonabarraga, J Kulisevsky
INTRODUCTION: The management of motor complications in Parkinson's disease (PD) is still limited. Safinamide, a new drug that has MAO-B inhibition and antiglutamatergic effects through inhibition of sodium channels, has shown efficacy for the treatment of fluctuations at doses of 50-100 mg/day. PATIENTS AND METHODS: From daily clinical practice, we describe the efficacy and tolerability of safinamide at three months in PD patients with motor complications. Efficacy was assessed by the Clinical Global Impression of Change scale and change in 'off' time during the daytime...
November 16, 2017: Revista de Neurologia
keyword
keyword
102823
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"